.RESEARCH HIGHLIGHT.06 August 2024.
A large randomized controlled test with cisgender ladies highlights the challenges of adherence to a day-to-day oral preexposure prevention program as well as shows that twice-yearly injection of lenacapavir may sustain effective HIV prevention levels over 6 months.